NCT04019561 - A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 23, 2019

Primary Completion Date

May 6, 2021

Study Completion Date

May 6, 2021

Conditions

Non-alcoholic Fatty Liver Disease (NAFLD)Non-alcoholic Steatohepatitis (NASH)

Interventions

DRUG

MEDI0382 high dose

MEDI0382 high dose administered subcutaneously

DRUG

Placebo for MEDI0382 high dose

Placebo for MEDI0382 high dose administered subcutaneously

DRUG

MEDI0382 low dose

MEDI0382 low dose administered subcutaneously

DRUG

Placebo for MEDI0382 low dose

Placebo for MEDI0382 low dose administered subcutaneously

Trial Locations (27)

23219

Research Site, Richmond

27705

Research Site, Durham

33016

Research Site, Hialeah

33125

Research Site, Miami

33157

Research Site, Palmetto Bay

33166

Research Site, Doral

33189

Research Site, Miami

37421

Research Site, Chattanooga

45242

Research Site, Blue Ash

70072

Research Site, Marrero

77002

Research Site, Houston

77084

Research Site, Houston

78215

Research Site, San Antonio

78229

Research Site, San Antonio

85712

Research Site, Tucson

89104

Research Site, Las Vegas

89109

Research Site, Las Vegas

90057

Research Site, Los Angeles

90505

Research Site, Torrance

91303

Research Site, Canoga Park

91763

Research Site, Montclair

91911

Research Site, Chula Vista

92093

Research Site, La Jolla

92118

Research Site, Coronado

92683

Research Site, Westminster

95648

Research Site, Lincoln

00927

Research Site, San Juan